Rilonacept

利纳西普

Report date: 2025/04/09 14:09:38

Base Information

Drug NameRilonacept
Drug Alias NameInterleukin-1 Trap利洛纳塞利那西普IL-1 Cytokine TrapRilonaceptum +[12] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-1 alpha inhibitorsInterleukin-1 beta inhibitors
TargetsInterleukin-1 alphaInterleukin-1 beta
Therapy Area/IndicationsMuckle-Wells Syndrome (MWS)Deficiency of interleukin-1 receptor antagonistInflammation +[22] 
Global Approved IndicationsMuckle-Wells Syndrome (MWS)Cryopyrin-Associated Periodic Syndromes
Approved Indications in ChinaMuckle-Wells Syndrome (MWS)Cryopyrin-Associated Periodic Syndromes
Original Approved Country/TerritoryUnited States
Original Approved Date2008/02/27
Country/TerritoryCanadaUnited StatesTaiwan +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesKiniksa Pharmaceuticals (UK) LtdJohns Hopkins UniversityKiniksa Pharmaceuticals Ltd
Inactive CompaniesUniversity of Texas Southwestern Medical CenterRegeneron Uk LtdCharite University, Berlin, Germany +[9] 
Active IndicationsMuckle-Wells Syndrome (MWS)Cryopyrin-Associated Periodic SyndromesSarcoidosis +[4] 
Inactive IndicationsDeficiency of interleukin-1 receptor antagonistInflammationSchnitzler Syndrome +[18] 

Other Information

ATC CodeL04AC04
Related LinksWikipediaDrugBankKEGG